Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL3841436 | 0.94 | SLC34A1 (0.50) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL19741591 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL28830501 | 0.94 | SLC34A1 (0.50) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL28492768 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL11047334 | 0.94 | SLC34A1 (0.50) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL4580763 | 0.94 | SLC34A1 (0.50) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL36117 | 0.94 | SLC34A1 (0.60) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL22451 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL10746522 | 0.94 | SLC34A1 (0.46) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL433859 | 0.94 | SLC34A1 (0.60) | SLC34A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789105-B | Hard carbon negative electrode material, negative electrode plate and secondary battery | 江苏正力新能电池技术股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240335521-A1 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | VAXCYTE, INC. | 2024-10-10 | — | — | US | claimed |
| EP-4395818-A1 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | VAXCYTE, INC. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-116120938-B | Soil restoration agent and preparation method and application thereof | 中国科学院广州地球化学研究所 | 2024-07-02 | — | — | CN | claimed |
| CN-117986376-A | Ii-Key hybrid and application thereof in preparation of tumor vaccine | 优峰(北京)生物科技有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-11890335-B2 | ErbB peptide pharmaceutical and vaccine compositions and therapeutic uses thereof for cancer | L2 DIAGNOSTICS, LLC (US) | 2024-02-06 | — | — | US | claimed |
| US-20240010690-A1 | ORAL VACCINE, METHOD OF PREPARATION AND USE THEREOF | FeedVax, Inc. | 2024-01-11 | — | — | US | claimed |
| CN-116789105-A | Hard carbon negative electrode material, negative electrode plate and secondary battery | 江苏正力新能电池技术有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116120938-A | Soil restoration agent and preparation method and application thereof | 中国科学院广州地球化学研究所 | 2023-05-16 | — | — | CN | claimed |
| WO-2023034932-A1 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | VAXCYTE, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| WO-2012069826-A1 | CALCIUM SULPHATE-BASED PRODUCTS AND METHODS FOR THE MANUFACTURE THEREOF | BPB LIMITED (GB) | 2012-05-31 | — | — | WO | claimed |
| WO-2011017442-A2 | ANTI-RSV IMMUNOGENS AND METHODS OF IMMUNIZATION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (US) | 2011-02-10 | — | — | WO | claimed |
| US-20110027349-A1 | POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIUM | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION | 2011-02-03 | — | — | US | claimed |
| EP-2244720-A2 | POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIUM | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009089535-A2 | POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIUM | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-07-16 | — | — | WO | claimed |
| US-20010051196-A1 | PROCESS FOR PRODUCING SOURDOUGH | GIST-BROCADES, B.V. (NL) | 2001-12-13 | — | — | US | claimed |
| EP-0815731-A1 | Process for producing sourdough | GIST-BROCADES B.V. (NL) | 1998-01-07 | — | — | EP | claimed |
| US-5039629-A | Hybrid ceramic composition and process for its manufacture | COR-LIN, INC. (US) | 1991-08-13 | — | — | US | claimed |
| US-4347325-A | SLURRYING POTASSIUM, ALUMINUM, PHOSPHATE SOURCES; SETTING OR CURING | STAUFFER CHEMICAL COMPANY (US) | 1982-08-31 | — | — | US | claimed |
| EP-0053422-A1 | Potassium-aluminum-phosphate compositions, process for the preparation thereof as well as articles and coatings made from said compositions | STAUFFER CHEMICAL COMPANY (US) | 1982-06-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890335-B2 | ErbB peptide pharmaceutical and vaccine compositions and therapeutic uses thereof for cancer | ERBB3, EGFR, ERBB2 | SLC34A1 2884/4885LMNA 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.